These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 19047899)

  • 1. An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia.
    Lu D; Vohra P; Chu PG; Woda B; Rock KL; Jiang Z
    Am J Surg Pathol; 2009 Apr; 33(4):521-5. PubMed ID: 19047899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
    Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
    Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of insulin-like growth factor II mRNA-binding protein 3 in human esophageal adenocarcinoma and its precursor lesions.
    Feng W; Zhou Z; Peters JH; Khoury T; Zhai Q; Wei Q; Truong CD; Song SW; Tan D
    Arch Pathol Lab Med; 2011 Aug; 135(8):1024-31. PubMed ID: 21809994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IMP3 Immunoreactivity is More Sensitive Than AMACR in Detecting Dysplastic Epithelium and Early Adenocarcinoma in Barrett Esophagus.
    Gadara MR; Gonzalez M; Cartun RW; Ligato S
    Appl Immunohistochem Mol Morphol; 2017 Jul; 25(6):386-391. PubMed ID: 26766126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rab11a immunohistochemical analysis does not distinguish indefinite, low-, and high-grade dysplasia in Barrett esophagus.
    Robert ME; Washington MK; Lee JR; Goldenring JR; Bronner MP; Goldblum JR; Greenson JK; Haber MM; Hart JA; Lamps LW; Lauwers GY; Lewin D; Lazenby AJ; Montgomery E; Crawford JM
    Am J Clin Pathol; 2005 Oct; 124(4):519-27. PubMed ID: 16146818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
    Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
    Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel biomarker for the detection of esophageal adenocarcinoma.
    Hammoud ZT; Badve S; Saxena R; Kesler KA; Rieger K; Malkas LH; Hickey RJ
    J Thorac Cardiovasc Surg; 2007 Jan; 133(1):82-7. PubMed ID: 17198786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma.
    Huhta H; Helminen O; Lehenkari PP; Saarnio J; Karttunen TJ; Kauppila JH
    Oncotarget; 2016 Apr; 7(17):23658-67. PubMed ID: 27008696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target.
    Hansel DE; Dhara S; Huang RC; Ashfaq R; Deasel M; Shimada Y; Bernstein HS; Harmon J; Brock M; Forastiere A; Washington MK; Maitra A; Montgomery E
    Am J Surg Pathol; 2005 Mar; 29(3):390-9. PubMed ID: 15725809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for enhanced telomerase activity in Barrett's esophagus with dysplasia and adenocarcinoma.
    Merchant NB; Dutta SK; Girotra M; Arora M; Meltzer SJ
    Asian Pac J Cancer Prev; 2013; 14(2):679-83. PubMed ID: 23621218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas.
    Washington K; Chiappori A; Hamilton K; Shyr Y; Blanke C; Johnson D; Sawyers J; Beauchamp D
    Mod Pathol; 1998 Sep; 11(9):805-13. PubMed ID: 9758359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.
    Hanas JS; Lerner MR; Lightfoot SA; Raczkowski C; Kastens DJ; Brackett DJ; Postier RG
    Cancer; 1999 Sep; 86(5):756-63. PubMed ID: 10463972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker.
    Turner JR; Odze RD; Crum CP; Resnick MB
    Hum Pathol; 1997 Jun; 28(6):740-4. PubMed ID: 9191010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
    Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
    Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.
    Glickman JN; Yang A; Shahsafaei A; McKeon F; Odze RD
    Hum Pathol; 2001 Nov; 32(11):1157-65. PubMed ID: 11727253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor II messenger RNA-binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm.
    Morimatsu K; Aishima S; Yamamoto H; Hayashi A; Nakata K; Oda Y; Shindo K; Fujino M; Tanaka M; Oda Y
    Hum Pathol; 2013 Sep; 44(9):1714-21. PubMed ID: 23597774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions.
    Montgomery E; Mamelak AJ; Gibson M; Maitra A; Sheikh S; Amr SS; Yang S; Brock M; Forastiere A; Zhang S; Murphy KM; Berg KD
    Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):24-30. PubMed ID: 16540726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDX2 and villin are useful markers of intestinal metaplasia in the diagnosis of Barrett esophagus.
    Shi XY; Bhagwandeen B; Leong AS
    Am J Clin Pathol; 2008 Apr; 129(4):571-7. PubMed ID: 18343784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Barrett esophagus--esophageal carcinoma: diagnosis].
    Schwacha H
    Praxis (Bern 1994); 2002 May; 91(20):877-80. PubMed ID: 12071089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic significance of nuclear p53 expression in the surveillance of Barrett's esophagus--a longitudinal study.
    Klump B; Hsieh CJ; Holzmann K; Borchard F; Gaco V; Greschniok A; Eckardt VF; Bettendorf U; Gregor M; Porschen R
    Z Gastroenterol; 1999 Oct; 37(10):1005-11. PubMed ID: 10549095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.